Connor, Clark & Lunn Investment Management (CC&L)’s Xeris Biopharma Holdings XERS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.73M | Buy |
1,227,959
+638,488
| +108% | +$2.98M | 0.02% | 536 |
|
|
2025
Q1 | $3.24M | Buy |
589,471
+418,139
| +244% | +$2.3M | 0.01% | 607 |
|
|
2024
Q4 | $581K | Buy |
171,332
+88,224
| +106% | +$299K | ﹤0.01% | 1105 |
|
|
2024
Q3 | $237K | Buy |
+83,108
| New | +$237K | ﹤0.01% | 1294 |
|
|
2022
Q2 | – | Sell |
-28,897
| Closed | -$74K | – | 1219 |
|
|
2022
Q1 | $74K | Buy |
+28,897
| New | +$74K | ﹤0.01% | 990 |
|